Derrell Porter Biography and Net Worth

Director of Acumen Pharmaceuticals

Dr. Porter is a physician-entrepreneur with more than 20 years of experience in drug development and commercialization. He is currently the CEO of cTRL Therapeutics, a next generation cell therapy company focused on solid tumors, leveraging circulating tumor reactive lymphocytes. Previously, he was founder and CEO of Cellevolve Bio, a development and commercialization cell therapy biotech focused on neglected diseases. Additionally, he served in commercial, strategy and corporate development roles at Atara Bio, Gilead, AbbVie and Amgen. He is also a Board Member at Passage Bio, a genetics medicine company developing therapeutics for disorders of the central nervous system and Portal Innovations, LLC, a venture development engine which delivers seed capital, specialized equipment, lab space, and management expertise to early-stage biotech companies.

Dr. Porter started his career at McKinsey & Company where he worked with multiple biopharmaceutical clients. He earned his M.D. from the Perelman School of Medicine and MBA from the Wharton School at the University of Pennsylvania, and his B.S. in Neuroscience from the University of California, Los Angeles.

What is Derrell Porter's net worth?: The estimated net worth of Derrell Porter is at least $79.52 thousand as of June 16th, 2026. Dr. Porter owns 35,500 shares of Acumen Pharmaceuticals stock worth more than $79,520 as of August 5th. This net worth estimate does not reflect any other investments that Dr. Porter may own. Learn More about Derrell Porter's net worth.
How do I contact Derrell Porter?: The corporate mailing address for Dr. Porter and other Acumen Pharmaceuticals executives is , , . Acumen Pharmaceuticals can also be reached via phone at 434-297-1000 and via email at [email protected]. Learn More on Derrell Porter's contact information.
Has Derrell Porter been buying or selling shares of Acumen Pharmaceuticals?: Derrell Porter has not been actively trading shares of Acumen Pharmaceuticals within the last three months. Most recently, Derrell Porter sold 13,040 shares of the business's stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $2.33, for a transaction totalling $30,383.20. Following the completion of the sale, the director now directly owns 35,500 shares of the company's stock, valued at $82,715. Learn More on Derrell Porter's trading history.
Who are Acumen Pharmaceuticals' active insiders?: Acumen Pharmaceuticals' insider roster includes Marc Benioff (CEO), Nathan Fountain (Director), Paul Manning (Director), Daniel O'Connell (Chief Executive Officer), Derrell Porter (Director), and John Stalfort, III (Director). Learn More on Acumen Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Acumen Pharmaceuticals?: During the last year, insiders at the sold shares 30 times. They sold a total of 188,518 shares worth more than $374,717.53. The most recent insider tranaction occured on June, 17th when Director Derrell Porter sold 13,040 shares worth more than $30,383.20. Insiders at Acumen Pharmaceuticals own 10.2% of the company. Learn More about insider trades at Acumen Pharmaceuticals.
Information on this page was last updated on 6/17/2026.

Derrell Porter Insider Trading History at Acumen Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/17/2026	Sell	13,040	$2.33	$30,383.20	35,500
6/16/2026	Sell	12,800	$2.33	$29,824.00	35,500
6/15/2026	Sell	6,460	$2.35	$15,181.00	48,300

Derrell Porter Buying and Selling Activity at Acumen Pharmaceuticals

Acumen Pharmaceuticals Company Overview

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Today's Range

Now: $2.27

$2.22

$2.29

50 Day Range

MA: $2.37

$2.11

$2.77

2 Week Range

Now: $2.27

$1.19

$3.60

Volume

23,482 shs

Average Volume

605,192 shs

Market Capitalization

$163.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.36